ClinicalTrials.gg
TerminatedNCT06106841Updated Dec 30, 2025

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Phase 1/2 interventional study of 400mg of TQB3909 tablets and 600mg of TQB3909 tablets in Mantle Cell Lymphoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Terminated at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Study terminated for strategic business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Lymphoma, Mantle-Cell with a site in China — 44 open to participants now, 56 under way, 10 of them phase 3. Lymphoma, Mantle-Cell · China.

Enrollment
77th of 91
19 · median 50
Started
2023
with 5 others
Phase 1/2
24 of 98
7 open now
Registered
64th of 98
by date

Among the 98 studies in Lymphoma, Mantle-Cell with a site in China, this one is the 77th largest by enrollment of the 91 interventional ones that give a count, is one of 6 that started in 2023, is one of 24 in phase 1/2, and was the 64th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

44 of the 98 studies in Lymphoma, Mantle-Cell with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Lymphoma, Mantle-Cell with a site in China, or all of them as a file.
02

Study summary

This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.

03

Conditions studied

  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject voluntarily joins the study, signs the form, and has good compliance;
  • Age: ≥ 18 years old (when signing the informed consent form); performance status (ECOG PS) score: 0-2 points; Expected survival is more than 3 months;
  • Subject population: Confirmed as MCL by local laboratory pathology and independent pathology review (stage 2).
  • The main organs are functioning well,
  • The patient's Computed Tomography (CT) / Magnetic Resonance Imaging (MRI) shows , defined as ≥ 1 lymph node with the longest diameter of > 1.5 cm or ≥ 1 extranodal lesion with the longest diameter of > 1.0 cm, which can be measured by ≥ 2 vertical dimensions;
  • Female subjects of childbearing age should agree to use (e.g., pills, or condoms) during the study and for 6 months after the end of the study; Have a negative serum pregnancy test within 7 days prior to study enrollment and must be a non-lactating subject; Male participants should agree that contraception must be used during the study period and for 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  • Have had or currently have other malignant tumors within 3 years before the first dose of study drug.
  • It is known that lymphoma affects the central nervous system (CNS);
  • Previous hematopoietic stem cell transplantation;
  • Have received autologous hematopoietic stem cell transplantation within 3 months before the first dose of study drug;
  • There are a variety of factors that affect oral drugs (such as inability to swallow, chronic diarrhea and intestinal obstruction, inflammatory bowel disease, malabsorption syndrome, etc.);
  • Unmitigated toxicity ≥ (CTCAE) grade 2 due to any prior treatment (except hair loss, and abnormalities, which follow the inclusion criteria 4);
  • Significant surgical treatment and obvious traumatic injury within 28 days prior to the start of study treatment;
  • Arteriovenous thrombotic events within 3 months before the first dose, such as cerebrovascular accident (including cerebral hemorrhage, cerebral infarction, except lacunar cerebral infarction), deep vein thrombosis (except secondary to deep vein catheterization) and pulmonary embolism;
  • Those who have a history of psychotropic substance abuse and cannot be withdrawn or have mental disorders;
  • Subjects with any severe and/or uncontrolled medical conditions, including:
  • Grade ≥2 myocardial ischemia or myocardial infarction, arrhythmia (Quick Time Constant Fluctuation () >450 ms in men, QTcF >470 ms in women) and grade ≥2 congestive heart failure ( (NYHA) grade), cardiac ultrasound assessment of (LVEF) of \<50%; poorly controlled hypertension, defined as systolic blood pressure > 170 mmHg and diastolic blood pressure > 105 mmHg at least 2 consecutive blood pressure measurements at the time of screening;
  • presence of active infection (≥ CTCAE grade 2 infection);
  • active hepatitis; virus (HBV) infection, HBV DNA positive or copy number exceeding the values in the research center;
  • Have a history of immunodeficiency, including (HIV)-positive or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;
  • Those who have epilepsy and need treatment.
  • Have received chemotherapy and radiotherapy within 4 weeks before the first dose, received and Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy 12 weeks before the first dose, and received other small molecule antitumor therapy (elution period from the end of the last treatment) before the first drug use within 5 half-lives;
  • Previous treatment with BCL-2 inhibitors;
  • Have received a within 4 weeks prior to the first dose, or plan to be vaccinated during the study;
  • Have participated in other antitumor drug clinical trials within 4 weeks before the first dose;
  • According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of subjects or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.
  • Allergic to allopurinol and benzbromarone.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    400mg of TQB3909 tablets

    tablet, 28 days as a treatment cycle.

    Drug: 400mg of TQB3909 tablets

  • Experimental
    600mg of TQB3909 tablets

    tablet, 28 days as a treatment cycle.

    Drug: 600mg of TQB3909 tablets

Interventions

  • Drug400mg of TQB3909 tablets

    TQB3909 tablets 400mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.

  • Drug600mg of TQB3909 tablets

    TQB3909 tablets 600mg, TQB3909 tablets is a B-cell lymphoma (BCL)-2 inhibitor.

06

What researchers measure

Primary outcomes

  1. Recommended phase II dose (RP2D)

    Recommended phase II dose (RP2D)

    Time frame: Baseline up to 48-weeks

Secondary outcomes

  1. The incidence of adverse events (AEs)

    Number of participants with adverse events (AE) and/or severe adverse events (SAE) and/or abnormal laboratory examination indicators.

    Time frame: Baseline up to 96-weeks

  2. The severity of adverse events (AEs)

    The severity of adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

    Time frame: Baseline up to 96-weeks

  3. The severity of severe adverse events (SAEs)

    The severity of severe adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

    Time frame: Baseline up to 96-weeks

  4. The severity of abnormal laboratory examination indicators

    The severity of abnormal laboratory examination indicators as assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0.

    Time frame: Baseline up to 96-weeks

07

Study locations

28 sites
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Chongqing University Hospital
    Chongqing, Chongqing Municipality 400030, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Gansu Provincial Cancer Hospital
    Lanzhou, Gansu 730050, China
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi 530021, China
  • The Affiliated Hospital of Chengde Medical College
    Chengde, Hebei 067000, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • Affiliated Cancer Hospital of Harbin Medical University
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
    Wuhan, Hubei 430050, China
  • The Affiliated Hospital of Xuzhou Medical University
    Nanjing, Jiangsu 220005, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215004, China
  • The First Affiliated Hospital Of Soochow University
    Suzhou, Jiangsu 215006, China
  • Jinzhou Central Hospital
    Wuxi, Jiangsu 530031, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130012, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130022, China
  • The Second Hospital of Dalian Medical University
    Dalian, Liaoning 116000, China
  • Binzhou Medical University Hospital
    Binzhou, Shandong 256603, China
  • Linyi People's Hospital
    Linyi, Shandong 276000, China
  • Shanghai Huashan Hospital
    Shanghai, Shanghai Municipality 200040, China
  • Tongji hospital of Tongji University
    Shanghai, Shanghai Municipality 200065, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi 046000, China
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300040, China
  • Institute of Dematology & Blood diseases Hospital
    Tianjin, Tianjin Municipality 300052, China
  • Xinjiang Uygur Autonomous Region People's Hospital
    Ürümqi, Xinjiang 830001, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang 215006, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Oct 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2023
First posted
Oct 30, 2023
StartActual
Oct 5, 2023
Primary completionActual
Oct 16, 2024
CompletionActual
Oct 16, 2024
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06106841
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Oct 5, 2023
Primary completion
Oct 16, 2024
Completion
Oct 16, 2024
Last update
Dec 30, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion